In summary, we put forward that targeting mature OLs is an untapped therapeutic avenue to support CNS health in the context of neurological disorders. This holds promise not only in the treatment of neurological disorders typically considered to be those of the white matter like MS, but also other neurodegenerative conditions where OL and myelin pathology have been described, such as Alzheimer’s disease, ALS, Huntington’s Disease, and Schizophrenia27–29,197,198. Furthering our understanding of the mechanisms driving sublethal and lethal injury of OLs is therefore a critical priority in expanding effective therapeutic options for a broad spectrum of neurological disorders across the lifespan.
